A Mer­ck an­tibi­ot­ic has been re­called af­ter re­ports of the pres­ence of glass par­tic­u­late mat­ter, the com­pa­ny an­nounced Tues­day.

One lot of Cu­bicin will be re­called, which in­cludes about 22,000 vials of the 500mg dose of the in­tra­venous­ly ad­min­is­tered drug.

The re­call comes af­ter a piece of glass was found in a vial, rais­ing safe­ty con­cerns.

“Our high­est pri­or­i­ties are the health and safe­ty of pa­tients and the qual­i­ty of our med­i­cines and vac­cines,” said Richard Haupt, the VP of vac­cines & in­fec­tious dis­eases. “We sin­cere­ly re­gret any in­con­ve­nience caused by this re­call.”

Cu­bicin treats skin in­fec­tions in both adults and chil­dren, and Staphy­lo­coc­cus au­reus in­fec­tions in chil­dren, and is pack­aged in sin­gle-dose, 10 mL glass vials.

Mer­ck is ar­rang­ing for the re­turn of the prod­ucts via UPS Next Day Air.

The FDA has been no­ti­fied of the re­call, Mer­ck said, though the FDA on Wednes­day post­ed the no­tice to its re­call page.

Sep­a­rate­ly, one lot of Bryant Ranch Prepack’s mus­cle re­lax­ers have been re­called as well. The Cal­i­for­nia-based com­pa­ny is re­call­ing 30- and 90-count bot­tles of metho­car­bamol 500mg af­ter some pack­ages of 500mg tablets were found to con­tain 750mg tablets.

If a pa­tient were to take a 750mg tablet, that could lead to ex­ces­sive cen­tral ner­vous sys­tem de­pres­sion, which re­sults in nau­sea, se­da­tion, faint­ing, seizures and co­mas. So far, there have not been any re­ports of side ef­fects re­sult­ing from the re­call.

The prod­uct can be iden­ti­fied by its red and white la­bel with a yel­low bor­der at the top and bot­tom of the pack­ag­ing. The drug was dis­trib­uted across the coun­try.

Quebec-based Medicago and its adjuvant partner GlaxoSmithKline said Tuesday that their plant-based Covid-19 vaccine candidate proved to be 71% efficacious against all variants of SARS-CoV-2 in a Phase III trial of more than 24,000 adults in Canada, the US, UK, Mexico, Argentina and Brazil.

In addition to showing 75% efficacy against the Delta variant specifically, the companies also said the vaccine proved to be generally safe, with no serious adverse events reported and reactogenicity generally being mild to moderate. The results mean that a regulatory submission will be filed with Health Canada imminently, they said.

Richard Lerner, the esteemed biochemist who pioneered a new way to develop monoclonal antibodies and led Scripps Research Institute to prominence, has passed away.

A spokesperson for Scripps told the San Diego Union-Tribune that Lerner died of cancer in his La Jolla home. He was 83 years old.

Among other things, Lerner’s lab was known for devising a new technique for creating antibodies — deployed as cancer treatments as well as in immunology and disease research — one that the New York Times called a “major advance in biotechnology.” It led to companies making mAbs a thousand times faster, more accurately, at a lower cost. That foundational research cemented the discovery of Humira, which went on to become the world’s best-selling treatment.